Goldman Sachs Asset Management, an investment manager, agreed to invest $230m in 4G Clinical, a developer of randomization and trial supply management software designed to accelerate clinical research. "This investment is transformational. In just over 5 years, 4G Clinical has grown from a start-up to a globally recognized leader in RTSM, helping life sciences organizations execute clinical trials of any size and complexity throughout the drug development lifecycle. To maximize our impact on lives around the globe, we must unwaveringly drive innovation in our technology and processes to tackle clinical trial bottlenecks. This investment from Goldman Sachs ensures that we will not be constrained in any way in that effort," David Kelleher, 4G Clinical CEO.